News | Pacemakers | June 20, 2017

Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases

European study finds devices may reveal time and cause of death when autopsy fails

Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases

June 20 2017 — Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European Heart Rhythm Association (EHRA) EUROPACE - CARDIOSTIM 2017 conference, June 18-21 in Vienna, Austria. Devices revealed the time and cause of death in some cases where autopsy failed to do so.

“In forensic medicine around 30 percent of cases remain unsolved because the cause or time of death after autopsy remains unclear,” said lead author Philipp Lacour, M.D., a cardiologist at Charité - Medical University of Berlin, Germany.

“The number of implanted cardiac devices with sophisticated diagnostic functions is increasing and we thought interrogating them might help to shed light on these unclear deaths,” he added. “Currently, device interrogation is not routinely performed after autopsy.”

The study was conducted in cooperation with the Department of Forensic Medicine at Charité - Medical University of Berlin where more than 5,000 autopsies were performed in a five-year period. Of these, 150 cases had an implantable cardiac device that was removed from the body during the autopsy.

The explanted devices included 107 pacemakers, 22 implantable cardioverter defibrillators (ICDs), 14 cardiac resynchronization therapy (CRT) systems and six implantable loop recorders. The devices were interrogated by two electrophysiologists to determine time and cause of death, and device failure.

Time of death could be determined in 76 percent of cases using data from the device. It could be identified precisely (to the minute) when the patient had tachycardia  at the end of life. In other cases, changes in seven parameters were used to assign the time of death. These included lead impedance and pacing threshold.

Lacour said, “At the end of life, lead impedance rises because of changes in the heart muscle and pacing climbs to 100 percent because the device doesn’t detect any heart rhythm.”

Cause of death was determined in 24 percent of cases. This included bradycardia, tachycardia, ventricular fibrillation and device malfunctions.

“The cause of death was most easily determined when the patient had a lethal arrhythmia such as tachycardia which was documented by the device,” said Lacour. “For example a ventricular fibrillation was recorded by a pacemaker, which did not intervene because it was not a defibrillator, and showed us that this arrhythmia caused the death.”

Device malfunction occurred in 7 percent of cases. This included hardware failure such as a broken lead, algorithm issues meaning the device did not recognize an arrhythmia or deliver a shock when it occurred, or a programming issue where the shock setting was insufficient to terminate an arrhythmia.

Lacour said, “In our study, the time or cause of death was unclear in about 30 percent of cases after autopsy alone. This dropped to around 10–20 percent using device interrogation. The two procedures provide complementary information and with the combination we can solve around 85 percent of all unclear deaths.”

“We think device interrogation should be routinely performed after autopsy in all forensic cases,” continued Lacour. “It helps determine the time and cause of death and identifies device malfunctions that might otherwise have gone unnoticed and should be highlighted to manufacturers and health departments.”

He concluded, “To ensure that accurate data is extracted from cardiac devices, the time between autopsy and device interrogation should be kept as short as possible and we try to do it within two weeks. This avoids the memory of the device filling up with artifacts that can be generated after the leads are cut.”

For more information: www.escardio.org


Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
Subscribe Now